Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Completed · Phase 2 · Has a placebo group

Conditions studied: Atopic Dermatitis

In brief

To assess the efficacy of multiple dupilumab dose-regimens, compared to placebo, in adult participants with moderate-to-severe atopic dermatitis (AD).

Key facts

Study ID

NCT01859988

Run by

Regeneron Pharmaceuticals

People needed

380

Starts

2013-05-01

Expected to finish

2014-09-01

Last updated by the study team

2017-08-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Mobile, Alabama, United States
• Study site — Tucson, Arizona, United States
• Study site — Bakersfield, California, United States
• Study site — San Diego, California, United States
• Study site — Santa Monica, California, United States
• Study site — Jacksonville, Florida, United States
• Study site — Ormond Beach, Florida, United States
• Study site — Skokie, Illinois, United States
• Study site — New Orleans, Louisiana, United States
• Study site — Andover, Massachusetts, United States
• Study site — Boston, Massachusetts, United States
• Study site — Troy, Michigan, United States
• Study site — St Louis, Missouri, United States
• Study site — New York, New York, United States
• Study site — Rochester, New York, United States
• Study site — Winston-Salem, North Carolina, United States
• Study site — Portland, Oregon, United States
• Study site — Pittsburgh, Pennsylvania, United States
• Study site — Johnston, Rhode Island, United States
• Study site — Greer, South Carolina, United States
• Study site — Nashville, Tennessee, United States
• Study site — Houston, Texas, United States
• Study site — San Antonio, Texas, United States
• Study site — Seattle, Washington, United States
• Study site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.